The study confirms both improved survival outcomes and reduced treatment-related toxicity compared to advanced photon therapy.
The trial reported a “five-year overall survival rate of 90.9% with IMPT versus 81.0% with IMRT,” corresponding to a “42% reduction in the hazard of death” for patients treated with proton therapy. In addition, the study demonstrated “significantly reduced rates of severe toxicities,” reinforcing proton therapy’s ability to better spare healthy tissue.
(Source: The Lancet,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01962-2/abstract)
IBA Proton Therapy described the publication as “an important milestone” that strengthens proton therapy’s position as a patient-focused treatment option with clear clinical advantages.
(Source: IBA, https://www.iba-worldwide.com/proton-therapy-new-standard-care-patients-oropharyngeal-cancer)
While these results underline the potential of proton therapy, translating clinical evidence into daily practice depends on the reliable and reproducible delivery of each treatment fraction. Precise patient setup is a critical factor in ensuring that planned dose distributions are accurately delivered.
This is where BizLink Healthcare contributes to the proton therapy ecosystem. Our ORION patient positioning system is designed to support high-precision and reproducible patient positioning, helping clinical teams consistently implement advanced treatment plans in routine clinical workflows.
As proton therapy continues to evolve toward evidence-based standard-of-care adoption, collaborative contributions across technology, delivery, and clinical practice remain essential to achieving optimal patient outcomes.
